Estrogen cancer therapy

A method of treating a patient diagnosed with cancer, and identified as having a postmenopausal estrogen level, wherein the cancer is characterized by presence of estrogen receptors on the cancer cells, or wherein the cancer originates in a tissue or organ containing estrogen receptor bearing cells, and wherein said treatment comprises administering to the patient an anti-cancer agent comprising a poly(amino acid) polymer conjugated to an anti-cancer drug, and estrogen therapy.

A method for selecting a cancer treatment regimen based on estradiol levels, comprising:

• determining whether the serum or plasma level of estrogen of a cancer patient is premenopausal, or postmenopausal, wherein a premenopausal estrogen level indicates that treatment with paclitaxel conjugated to polyglutamate will be more effective than unconjugated paclitaxel, and wherein a low postmenopausal estrogen level in serum or plasma indicates that treatment with paclitaxel conjugated to polyglutamate will be no more effective than unconjugated paclitaxel.